51671-71-7

Basic information

• Product Name: Benzoic acid, 2-(4-methoxy-3-methylbenzoyl)-
• CAS NO: 51671-71-7
• Molecular Formula: C16H14O4
• Molecular Weight: 270.285
• Mol File: 51671-71-7.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 2-(4-methoxy-3-methylbenzoyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 2-(4-methoxy-3-methylbenzoyl)-(51671-71-7)
• EPA Substance Registry System: Benzoic acid, 2-(4-methoxy-3-methylbenzoyl)-(51671-71-7)

Safety Data

• Hazardous Substances Data: 51671-71-7(Hazardous Substances Data)

Upstream product

• 85-44-9 phthalic anhydride 
• 14804-31-0 2-methyl-4-bromoanisole 
• 95-48-7 ortho-cresol 
• 117896-10-3 (4-methoxy-3-methylphenyl)magnesium bromide 
• 51671-72-8 2-(3-methyl-4-hydroxybenzoyl)benzoic acid 
• 77-78-1 dimethyl sulfate 
• 80-48-8 methyl p-toluene sulfonate 
• 578-58-5 2-methylmethoxybenzene 

Downstream Products

• 17241-40-6 3-hydroxy-2-methylanthraquinone 
• 17241-42-8 2-methoxy-3-methyl-9,10-anthraquinone 
• 860562-46-5 6'-methoxy-2,3'-carbonyl-di-benzoic acid 
• 1026435-08-4 2-(4-Methoxy-3-methyl-benzyl)-benzoic acid 
• 750637-86-6 4-(4-methoxy-3-methylphenyl)-1(2H)-phthalazinone 
• 750637-87-7 4-(4-methoxy-3-methylphenyl)-1-chlorophthalazine 
• 750637-88-8 4-(4-methoxy-3-methylphenyl)-1-hydrazinophthalazine 
• 362521-97-9 2-[2-(3-methyl-4-methoxyhydroxyiminobenzyl)phenyl]-4(H)-3,1-benzoxazin-4-one 

Relevant articles and documents

Further optimization of the M5 NAM MLPCN probe ML375: Tactics and challenges

This Letter describes the continued optimization of the MLPCN probe ML375, a highly selective M5 negative allosteric modulator (NAM), through a combination of matrix libraries and iterative parallel synthesis. True to certain allosteric ligands, SAR was shallow, and the matrix library approach highlighted the challenges with M5 NAM SAR within in this chemotype. Once again, enantiospecific activity was noted, and potency at rat and human M5 were improved over ML375, along with slight enhancement in physiochemical properties, certain in vitro DMPK parameters and CNS distribution. Attempts to further enhance pharmacokinetics with deuterium incorporation afforded mixed results, but pretreatment with a pan-P450 inhibitor (1-aminobenzotriazole; ABT) provided increased plasma exposure.